Background: Transformation of follicular lymphoma into an aggressive lymphoma (tFL) worsens the prognosis and the standard treatment is not completely defined. Allogeneic hematopoietic stem cell transplantation (alloSCT) could be a potentially curative option for these patients, but it has not been widely explored.
Methods: We designed a retrospective multicenter study to analyze the efficacy and toxicity of alloSCT in tFL patients and potential prognostic factors of survival.
Results: A total of 43 patients diagnosed with tFL who underwent alloSCT in 14 Spanish centers between January 2000 and January 2019 were included. Median age was 44 (31-67) years. After a median follow-up of 58 months, estimated 5-year overall survival (OS) and progression-free survival (PFS) were both 35%. Estimated 100-day and 1-year non-relapse mortality (NRM) were 20% and 34%, respectively. The type of conditioning regimen (3-year OS of 52% vs. 20%, respectively, for reduced-intensity vs. myeloablative conditioning) and development of chronic graft versus host disease (cGVHD) (3-year OS of 75% vs. 40%) were the only factors significantly associated with OS. The only variable with an independent association with OS was cGVHD (HR, 3.4; 95% CI, 1.2-9.6).
Conclusions: Our results indicate that alloSCT continues to be a potentially curative option for patients with tFL.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688508 | PMC |
| http://dx.doi.org/10.3390/cancers14225670 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Apolipoprotein E (APOE) has multiple functions in metabolism and immunoregulation. Its common germline variants APOE2, APOE3 and APOE4 give rise to three functionally distinct gene products. Previous studies reported yin-yang roles of APOE2 and APOE4 in immunological processes, but their effects in hematopoietic stem cell transplantation (HSCT) have never been studied.
View Article and Find Full Text PDFGynecological complications and treatment strategies in patients after hematopoietic stem cell transplantation.
Ginekol Pol
January 2025
Faculty of Medicine, Lazarski University, Warsaw, Poland, Poland.
In women after hematopoietic stem cell transplantation (HSCT), complications associated with the original disease and therapies used both before and after transplantation often occur, which significantly affects their quality of life. The most common gynaecological complications include secondary cancers, premature ovarian insufficiency (POI), infertility and chronic graft-versus-host disease (cGVHD). Cervical cancer is the most common secondary genital cancer in patients after HSCT.
View Article and Find Full Text PDFThe Importance of Cellular Therapy in the Clinical Case of a Young Man With a Challenging Precursor B-cell Lymphoblastic Leukemia.
Cureus
December 2024
Cellular Therapy Department, Instituto Português de Oncologia do Porto Fernando Gentil, Entidades Públicas Empresariais (EPE), Porto, PRT.
Acute lymphoblastic leukemia (ALL) poses a significant challenge due to its high relapse rate despite initial chemotherapy. Cell therapy plays an important and promising role in refractory ALL cases. The aim is to present a complex case of a 20-year-old male patient with relapsed ALL and to explore the different therapeutic options of cellular therapy - allogeneic hematopoietic stem cell transplantation, donor lymphocyte infusion, and chimeric antigen receptor T - detailing the collection, processing, and infusion, as well as the associated complications and management strategies.
View Article and Find Full Text PDFSuccessful Use of a Midline Catheter for Leukapheresis in Patients Undergoing Collection for Immune Effector Cell Therapy, Donor Lymphocyte Infusion, and Hematopoietic Progenitor Cell Collection.
J Clin Apher
February 2025
University of Kansas Medical Center, Division of Hematologic Malignancies and Cellular Therapeutics, Kansas City, Kansas, USA.
Apheresis is essential to conducting hematopoietic cell transplantation and genetically engineered cellular therapy procedures. Many patients and donors require central venous catheter (CVC) access for apheresis due to lack of adequate peripheral venous access. CVC placement has risks of associated complications and requires additional institutional resources and expertise.
View Article and Find Full Text PDFHow I Treat Higher-Risk MDS.
Blood
January 2025
H. Lee Moffitt Cancer Center, Tampa, Florida, United States.
Myelodysplastic syndromes/neoplasms (MDS) are a widely heterogenous group of myeloid malignancies characterized by morphologic dysplasia, a defective hematopoiesis, and recurrent genetic abnormalities. The original and revised International Prognostic Scoring Systems (IPSS) have been used to risk-stratify patients with MDS to guide treatment strategies. In higher-risk MDS, the therapeutic approach is geared toward delaying leukemic transformation and prolonging survival.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!